Summary

The global cell therapy technologies market is projected to reach USD 7.91 billion in 2030 from USD 4.41 billion in 2025, with a significant CAGR of 12.4% from 2025 to 2030. The market is experiencing strong growth, driven by advancements in regenerative medicine, the rising prevalence of chronic diseases, increasing investments in research and development, and innovations in gene editing tools, such as CRISPR. Regulatory support and government funding, along with strategic collaborations between biotech firms and academic institutions, are propelling the development of novel cell therapies, thereby driving market growth.

https://mnmimg.marketsandmarkets.com/Images/cell-therapy-technologies-market-img-overview.webp

“The T-cells segment is projected to record the highest CAGR during the forecast period.”
The cell therapy technologies market is categorized into three primary categories based on cell type: T cells, stem cells, and other cell types. The T-cell segment is expected to grow at the fastest rate during the forecast period, driven by the strong clinical and commercial momentum of CAR-T and TCR therapies in cancer and their expansion into solid tumor indications. Furthermore, increasing regulatory approvals, favorable reimbursement decisions in significant markets, and growing physician familiarity with T-cell immunotherapies are encouraging broader adoption, which in turn boosts demand for specialized media, gene-editing tools, bioreactors, and analytics tailored to T-cell workflows within the cell therapy technology market.
“The cancer application segment accounted for the largest share in 2024.”
The application segment in the cell therapy technologies market includes cancer, cardiovascular disease (CVD), orthopaedic disorders, autoimmune diseases, and other applications. The cancer application segment dominated in 2024 due to the increasing prevalence of cancer globally and the rising demand for innovative, targeted therapies. Advancements in cell engineering, scalable manufacturing, and emerging applications in solid tumors further enhance the growth potential of this segment. It possesses a solid clinical pipeline, and government initiatives are highly supportive, with regulatory approvals facilitating the segment's growth.
“The US dominated the North American cell therapy technologies market in 2024.”
The US is the largest biopharmaceutical market globally and a key hub for cell and gene therapy innovation, making it a core demand center for cell therapy technologies, products, and services. Demand is expected to rise further, supported by a sophisticated research ecosystem, strong venture and public funding, and the presence of foremost CGT technology leaders, including Thermo Fisher Scientific, Danaher, and Merck. The country benefits from substantial NIH and BARDA support for advanced therapies, as well as large precision medicine and population?scale CGT initiatives run through leading academic and cancer centers. The high uptake of automated cell processing platforms, digital manufacturing, and advanced analytics across clinical and commercial facilities reinforces the US market's leadership. In addition, a mature regulatory framework, robust healthcare infrastructure, and active public?private collaborations continue to foster rapid translation and commercialization of new cell therapy technologies in the US.
The primary interviews conducted for this report can be categorized as follows:

? By Respondent: Supply Side (70%) and Demand Side (30%)
? By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
? By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)
Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), Agilent Technologies Inc. (US), Avantor, Inc. (US), Bio-Techne (US), Fresenius SE & Co KGAA (Germany), BD (US), Corning Incorporated (US), Terumo Corporation (Japan), GenScript (US), MaxCyte (US) and STEMCELL Technologies (Canada) are some of the major players operating in the cell therapy technologies market.
Research Coverage:
This research report categorizes the cell therapy technologies market by product (media, sera, and reagents; cell engineering products; cell culture vessels; cell therapy equipment; systems & software; and other products), process (cell processing, cell preservation, cell distribution, cell handling, and process monitoring & quality control), cell type (T-cells, stem cells, and other cells), application (cancer, cardiovascular disease (CVD), orthopedic disorders, autoimmune diseases, and other applications) end user (biopharmaceutical & biotechnology companies, CROs & CMOs, research institutes, and cell banks), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa). The report’s scope encompasses detailed information regarding the key factors, including drivers, restraints, challenges, and opportunities, that influence market growth. A thorough analysis of key industry players has provided insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations, and acquisitions are recent developments in the cell therapy technologies market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell therapy technologies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
? Analysis of key drivers (expanding base of approved CGTs and a growing clinical pipeline, growing capital investments in CGT manufacturing capacity, scale-up of allogeneic and iPSC-derived platforms) restraints (high therapy cost and uncertain reimbursement limiting commercial volumes), opportunities (platformized, modular manufacturing solutions for autologous therapies, integration with digital technologies such as AI & ML), and challenges (lack of skilled workforce in CGT manufacturing and automation) influencing the growth of the market.
? Product Development/Innovation: Detailed insights on newly launched products of the cell therapy technologies market.
? Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
? Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell therapy technologies market.
? Competitive Assessment: Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), among others in the market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 40
1.1 STUDY OBJECTIVES 40
1.2 MARKET DEFINITION 40
1.3 STUDY SCOPE 40
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 41
1.3.2 INCLUSIONS & EXCLUSIONS 42
1.3.3 YEARS CONSIDERED 42
1.3.4 CURRENCY CONSIDERED 42
1.4 STAKEHOLDERS 43
1.5 SUMMARY OF CHANGES 43
2 EXECUTIVE SUMMARY 45
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 45
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 46
2.3 DISRUPTIVE TRENDS SHAPING MARKET 47
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 48
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 49
3 PREMIUM INSIGHTS 50
3.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW 50
3.2 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT AND COUNTRY, 2024 51
3.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2025 VS. 2030 52
3.4 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52
4 MARKET OVERVIEW 53
4.1 INTRODUCTION 53
4.2 MARKET DYNAMICS 53
4.2.1 DRIVERS 54
4.2.1.1 Expanding base of approved CGTs and growing clinical pipeline 54
4.2.1.2 Large capital investments in CGT manufacturing capacity 54
4.2.1.3 Growing shift towards closed and automated manufacturing 55
4.2.2 RESTRAINTS 55
4.2.2.1 Manufacturing and logistical complexity 55
4.2.2.2 High therapy cost and uncertain reimbursement limit commercial volumes 56
4.2.3 OPPORTUNITIES 56
4.2.3.1 Platformized and modular manufacturing solutions for autologous therapies 56
4.2.3.2 Development of personalized and off-the-shelf cell therapies 57
4.2.3.3 Integration with digital technologies 57
4.2.4 CHALLENGES 58
4.2.4.1 Lack of skilled workforce in CGT manufacturing and automation 58
4.3 UNMET NEEDS & WHITE SPACES 58
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 59
4.5 STRATEGIC MOVES BY TIER 1/2/3 COMPANIES 59
5 INDUSTRY TRENDS 60
5.1 PORTER’S FIVE FORCES ANALYSIS 60
5.1.1 THREAT OF NEW ENTRANTS 61
5.1.2 THREAT OF SUBSTITUTES 61
5.1.3 BARGAINING POWER OF BUYERS 61
5.1.4 BARGAINING POWER OF SUPPLIERS 61
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 61
5.2 MACROECONOMIC OUTLOOK 62
5.2.1 INTRODUCTION 62
5.2.2 GDP TRENDS AND FORECAST 62
5.2.3 TRENDS IN CELL THERAPY TECHNOLOGIES MARKET 63
5.2.4 R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY 63
5.2.5 R&D TRENDS IN GLOBAL PHARMA INDUSTRY 63
5.3 ECOSYSTEM ANALYSIS 64
5.3.1 ROLE IN ECOSYSTEM 64
5.4 PRICING ANALYSIS 65
5.4.1 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS, BY KEY PLAYER, 2022?2024 66
5.4.2 AVERAGE SELLING PRICE TREND OF CELL THERAPY EQUIPMENT, BY REGION, 2022?2024 67
5.5 VALUE CHAIN ANALYSIS 68
5.6 TRADE ANALYSIS 70
5.6.1 IMPORT SCENARIO FOR HS CODE 854330 70
5.6.2 IMPORT VOLUME FOR HS CODE 854330 71
5.6.3 EXPORT SCENARIO FOR HS CODE 854330, 2020?2024 71
5.6.4 EXPORT VOLUME FOR HS CODE 854330 72
5.7 KEY CONFERENCES AND EVENTS, 2026 73
5.8 INVESTMENT & FUNDING SCENARIO 73
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 75
5.10 IMPACT OF 2025 US TARIFF ON CELL THERAPY TECHNOLOGIES MARKET 76
5.10.1 KEY TARIFF RATES 76
5.10.2 PRICE IMPACT ANALYSIS 78
5.10.3 KEY IMPACT ON COUNTRIES/ REGION 78
5.10.3.1 US 78
5.10.3.2 Europe 79
5.10.3.3 Asia Pacific 79
5.10.4 END-USE INDUSTRY IMPACT 79
5.10.4.1 Biopharmaceutical and Biotechnology Companies 79
5.10.4.2 CROs and CMOs 80
5.10.4.3 Cell Banks 80
6 TECHNOLOGICAL ADVANCEMENTS, AI IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 81
6.1 TECHNOLOGY ANALYSIS 81
6.1.1 KEY EMERGING TECHNOLOGIES 81
6.1.1.1 Magnetic-activated cell sorting 81
6.1.1.2 Cryopreservation 81
6.1.1.3 Bioprocessing technologies 81
6.1.2 COMPLEMENTARY TECHNOLOGIES 82
6.1.2.1 Artificial intelligence and machine learning 82
6.1.2.2 Gene editing technologies 82
6.1.3 ADJACENT TECHNOLOGIES 82
6.1.3.1 Nanotechnology 82
6.1.3.2 Immunotherapy platforms 83
6.2 TECHNOLOGY/PRODUCT ROADMAP 83
6.3 PATENT ANALYSIS 83
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR CELL THERAPY TECHNOLOGIES PATENTS, 2014?2024 84
6.4 FUTURE APPLICATIONS 86
6.5 IMPACT OF AI/GEN AI ON CELL THERAPY TECHNOLOGIES MARKET 86
6.5.1 TOP USE CASES AND MARKET POTENTIAL 87
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN CELL THERAPY TECHNOLOGIES MARKET 88
6.5.3 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN CELL THERAPY TECHNOLOGIES MARKET 88
7 SUSTAINABILITY AND REGULATORY LANDSCAPE 90
7.1 REGULATORY LANDSCAPE 90
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
7.1.2 INDUSTRY STANDARDS 92
7.1.2.1 North America 93
7.1.2.2 Europe 93
7.1.2.3 Asia Pacific 93
7.1.2.4 Rest of the World 94
7.1.3 SUSTAINABILITY INITIATIVES, IMPACT, AND REGULATORY POLICY INITIATIVES 94
7.1.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 95
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 96
8.1 DECISION-MAKING PROCESS 96
8.2 KEY STAKEHOLDERS & BUYING CRITERIA 96
8.2.1 KEY STAKEHOLDERS 96
8.2.2 BUYING CRITERIA 97
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 99
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 100
9 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT 101
9.1 INTRODUCTION 102
9.2 MEDIA, SERA, AND REAGENTS 102
9.2.1 KEY IMPORTANCE OF MEDIA, SERA, AND REAGENTS IN CELL PROCESSING TO DRIVE MARKET 102
9.3 CELL THERAPY EQUIPMENT 106
9.3.1 CELL PROCESSING EQUIPMENT 109
9.3.1.1 Development of automated and closed-system cell processing equipment to accelerate segment growth 109
9.3.2 SINGLE-USE EQUIPMENT 112
9.3.2.1 Increasing funding for stem cell therapy to propel market growth 112
9.3.3 OTHER CELL THERAPY EQUIPMENT 115
9.4 SYSTEMS & SOFTWARE 117
9.4.1 GROWING NEED FOR CELL THERAPIES TO AID SYSTEMS AND SOFTWARE ADOPTION 117
9.5 CELL CULTURE VESSELS 121
9.5.1 RISING R&D AND INVESTMENTS IN CELL-BASED THERAPIES TO AUGMENT MARKET DEMAND 121
9.6 CELL ENGINEERING PRODUCTS 123
9.6.1 AVAILABILITY OF WIDE RANGE OF CELL ENGINEERING PRODUCTS TO SUPPORT MARKET GROWTH 123
9.7 OTHER PRODUCTS 127
10 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS 130
10.1 INTRODUCTION 131
10.2 CELL PROCESSING 131
10.2.1 CELL EXPANSION 134
10.2.1.1 Rising demand for personalized and regenerative therapies to drive market growth 134
10.2.2 CELL ISOLATION 137
10.2.2.1 Rising need for scalable and efficient isolation technologies to aid market growth 137
10.2.3 CELL CHARACTERIZATION 140
10.2.3.1 Increasing demand for high-quality, safe, and effective cell-based therapies to propel market growth 140
?
10.2.4 CELL COLLECTION 143
10.2.4.1 Advancements in cell collection technologies to propel market growth 143
10.3 CELL PRESERVATION 145
10.3.1 ADVANCEMENT IN CRYOPRESERVATION TECHNOLOGIES TO BOOST MARKET GROWTH 145
10.4 PROCESS MONITORING & QUALITY CONTROL 148
10.4.1 INCREASING DEMAND FOR AUTOMATED QUALITY CONTROL IN CELL THERAPY PRODUCTION TO FUEL MARKET GROWTH 148
10.5 CELL HANDLING 151
10.5.1 INCREASING DEMAND FOR AUTOMATED, EFFICIENT, AND SCALABLE SOLUTIONS TO ACCELERATE MARKET GROWTH 151
10.6 CELL DISTRIBUTION 154
10.6.1 INCREASED FOCUS ON TRANSPORTATION AND STORAGE TO DRIVE MARKET 154
11 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE 157
11.1 INTRODUCTION 158
11.2 T CELLS 158
11.2.1 GROWING RESEARCH ON CAR T-CELL THERAPY TO AID MARKET GROWTH 158
11.3 STEM CELLS 161
11.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO PROPEL MARKET GROWTH 161
11.4 OTHER CELLS 164
12 CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION 167
12.1 INTRODUCTION 168
12.2 CANCER 168
12.2.1 FOCUS ON CAR T-CELL INNOVATION TO DRIVE SEGMENT EXPANSION 168
12.3 CARDIOVASCULAR DISEASES 171
12.3.1 INCREASING FOCUS ON INNOVATIVE CELL THERAPY APPROACHES TO DRIVE MARKET 171
12.4 ORTHOPEDIC DISORDERS 174
12.4.1 GROWING ADOPTION OF STEM CELL THERAPY FOR TISSUE REPAIR TO SUPPORT MARKET GROWTH 174
12.5 AUTOIMMUNE DISEASES 177
12.5.1 RISING INVESTMENTS IN STEM CELL RESEARCH TO FUEL MARKET GROWTH 177
12.6 OTHER APPLICATIONS 180
13 CELL THERAPY TECHNOLOGIES MARKET, BY END USER 184
13.1 INTRODUCTION 185
13.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 185
13.2.1 GROWING ADOPTION OF INORGANIC GROWTH STRATEGIES BY BIOPHARMACEUTICAL COMPANIES TO SUPPORT MARKET GROWTH 185
?
13.3 CROS & CMOS 189
13.3.1 GROWING FOCUS ON OUTSOURCING CLINICAL-SCALE PRECLINICAL & CLINICAL TRIALS TO DRIVE GROWTH 189
13.4 RESEARCH INSTITUTES 192
13.4.1 RISING FOCUS ON RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH 192
13.5 CELL BANKS 195
13.5.1 INCREASING DEMAND FOR STANDARDIZED CELL LINES TO SPUR MARKET GROWTH 195
14 CELL THERAPY TECHNOLOGIES MARKET, BY REGION 199
14.1 INTRODUCTION 200
14.2 NORTH AMERICA 200
14.2.1 US 204
14.2.1.1 US to dominate North American cell therapy technologies market during forecast period 204
14.2.2 CANADA 207
14.2.2.1 Favorable funding scenario to drive adoption of cell therapy instruments 207
14.3 EUROPE 210
14.3.1 GERMANY 213
14.3.1.1 Well-established pharmaceutical and R&D industry to aid Germany gain significant European market share 213
14.3.2 UK 216
14.3.2.1 Favorable funding and investment scenario to fuel market growth 216
14.3.3 FRANCE 220
14.3.3.1 Availability of government and private funding to fuel market growth 220
14.3.4 ITALY 223
14.3.4.1 Increased focus on public and private investment to offer growth opportunities 223
14.3.5 SPAIN 226
14.3.5.1 Advancement in personalized medicines to stimulate market growth 226
14.3.6 REST OF EUROPE 229
14.4 ASIA PACIFIC 232
14.4.1 CHINA 235
14.4.1.1 Focus on innovation and R&D in genetic research to drive market 235
14.4.2 JAPAN 238
14.4.2.1 Strong availability of funding for advanced cell therapies to aid market growth 238
14.4.3 INDIA 241
14.4.3.1 Substantial government R&D investments and focus of academic institutions on scientific innovation to drive market 241
14.4.4 SOUTH KOREA 244
14.4.4.1 Rising number of alliances and investments in research to boost market growth 244
?
14.4.5 AUSTRALIA 247
14.4.5.1 Increasing government funding and initiatives to drive market growth 247
14.4.6 REST OF ASIA PACIFIC 250
14.5 LATIN AMERICA 253
14.5.1 BRAZIL 257
14.5.1.1 Growing development of advanced therapies and robust pharmaceutical & biotechnology sectors to aid market growth 257
14.5.2 MEXICO 260
14.5.2.1 Growing pharmaceutical industry and rising government support to aid market growth 260
14.5.3 REST OF LATIN AMERICA 263
14.6 MIDDLE EAST 266
14.6.1 GCC COUNTRIES 268
14.6.1.1 Kingdom of Saudi Arabia 271
14.6.1.1.1 Increasing government investments in healthcare to support market growth 271
14.6.1.2 UAE 275
14.6.1.2.1 Growing R&D expenditure and well-established class infrastructure to spur market growth 275
14.6.1.3 Rest of GCC Countries 278
14.6.2 REST OF MIDDLE EAST 281
14.7 AFRICA 283
14.7.1 INCREASING HEALTH AND RESEARCH SPENDING TO PROPEL MARKET DEMAND FOR ADVANCED CELL THERAPY TECHNOLOGIES 283
15 COMPETITIVE LANDSCAPE 287
15.1 INTRODUCTION 287
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 287
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET 287
15.3 REVENUE ANALYSIS, 2022?2024 288
15.4 MARKET SHARE ANALYSIS, 2024 289
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 291
15.5.1 STARS 291
15.5.2 EMERGING LEADERS 291
15.5.3 PERVASIVE PLAYERS 292
15.5.4 PARTICIPANTS 292
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 293
15.5.5.1 Company footprint 293
15.5.5.2 Region footprint 293
15.5.5.3 Product footprint 294
15.5.5.4 Cell type footprint 295
15.5.5.5 Application footprint 296
?
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 297
15.6.1 PROGRESSIVE COMPANIES 297
15.6.2 RESPONSIVE COMPANIES 297
15.6.3 DYNAMIC COMPANIES 297
15.6.4 STARTING BLOCKS 297
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 298
15.6.5.1 Detailed list of key startups/SMEs 298
15.6.5.2 Competitive benchmarking of startups/SMEs 299
15.7 COMPANY VALUATION & FINANCIAL METRICS 300
15.7.1 FINANCIAL METRICS 300
15.7.2 COMPANY VALUATION 300
15.8 BRAND/PRODUCT COMPARISON 301
15.9 COMPETITIVE SCENARIO 301
15.9.1 PRODUCT LAUNCHES 301
15.9.2 DEALS 302
15.9.3 EXPANSIONS 303
16 COMPANY PROFILES 304
16.1 KEY PLAYERS 304
16.1.1 DANAHER CORPORATION 304
16.1.1.1 Business overview 304
16.1.1.2 Products offered 305
16.1.1.3 Recent developments 310
16.1.1.3.1 Product launches 310
16.1.1.3.2 Deals 310
16.1.1.3.3 Expansions 311
16.1.1.4 MnM view 312
16.1.1.4.1 Key strengths 312
16.1.1.4.2 Strategic choices 312
16.1.1.4.3 Weaknesses & competitive threats 312
16.1.2 MERCK KGAA 313
16.1.2.1 Business overview 313
16.1.2.2 Products offered 314
16.1.2.3 Recent developments 316
16.1.2.3.1 Deals 316
16.1.2.3.2 Expansions 317
16.1.2.4 MnM view 317
16.1.2.4.1 Key strengths 317
16.1.2.4.2 Strategic choices 317
16.1.2.4.3 Weaknesses & competitive threats 317
?
16.1.3 THERMO FISHER SCIENTIFIC INC. 318
16.1.3.1 Business overview 318
16.1.3.2 Products offered 319
16.1.3.3 Recent developments 330
16.1.3.3.1 Product launches 330
16.1.3.3.2 Deals 331
16.1.3.3.3 Expansions 331
16.1.3.4 MnM view 332
16.1.3.4.1 Key strengths 332
16.1.3.4.2 Strategic choices 332
16.1.3.4.3 Weaknesses & competitive threats 332
16.1.4 LONZA 333
16.1.4.1 Business overview 333
16.1.4.2 Products offered 334
16.1.4.3 Recent developments 338
16.1.4.3.1 Product launches 338
16.1.4.3.2 Deals 339
16.1.4.3.3 Expansions 339
16.1.4.4 MnM view 339
16.1.4.4.1 Key strengths 339
16.1.4.4.2 Strategic choices 340
16.1.4.4.3 Weaknesses & competitive threats 340
16.1.5 SARTORIUS AG 341
16.1.5.1 Business overview 341
16.1.5.2 Products offered 342
16.1.5.3 Recent developments 346
16.1.5.3.1 Deals 346
16.1.5.3.2 Expansions 346
16.1.5.4 MnM view 347
16.1.5.4.1 Key strengths 347
16.1.5.4.2 Strategic choices 347
16.1.5.4.3 Weaknesses & competitive threats 347
16.1.6 AGILENT TECHNOLOGIES, INC. 348
16.1.6.1 Business overview 348
16.1.6.2 Products offered 349
16.1.6.3 Recent developments 350
16.1.6.3.1 Product launches 350
16.1.6.3.2 Deals 351
16.1.6.4 MnM view 351
16.1.6.4.1 Key strengths 351
16.1.6.4.2 Strategic choices 351
16.1.6.4.3 Weaknesses & competitive threats 351
16.1.7 AVANTOR, INC. 352
16.1.7.1 Business overview 352
16.1.7.2 Products offered 353
16.1.7.3 Recent developments 359
16.1.7.3.1 Product launches 359
16.1.7.3.2 Deals 359
16.1.8 FRESENIUS SE & CO. KGAA 360
16.1.8.1 Business overview 360
16.1.8.2 Products offered 361
16.1.8.3 Recent developments 362
16.1.8.3.1 Deals 362
16.1.9 BECTON, DICKINSON AND COMPANY (BD) 363
16.1.9.1 Business overview 363
16.1.9.2 Products offered 364
16.1.9.3 Recent developments 366
16.1.9.3.1 Product launches 366
16.1.9.3.2 Deals 366
16.1.10 CORNING INCORPORATED 367
16.1.10.1 Business overview 367
16.1.10.2 Products offered 368
16.1.11 TERUMO CORPORATION 372
16.1.11.1 Business overview 372
16.1.11.2 Products offered 373
16.1.11.3 Recent developments 374
16.1.11.3.1 Product launches 374
16.1.11.3.2 Deals 374
16.1.11.3.3 Expansions 375
16.1.12 BIO-TECHNE 376
16.1.12.1 Business overview 376
16.1.12.2 Products offered 377
16.1.12.3 Recent developments 383
16.1.12.3.1 Product launches 383
16.1.12.3.2 Deals 383
16.1.12.3.3 Other developments 383
16.1.13 GENSCRIPT 384
16.1.13.1 Business overview 384
16.1.13.2 Products offered 385
16.1.13.3 Recent developments 387
16.1.13.3.1 Deals 387
16.1.13.3.2 Other developments 388
?
16.1.14 MAXCYTE 389
16.1.14.1 Business overview 389
16.1.14.2 Products offered 390
16.1.14.3 Recent developments 392
16.1.14.3.1 Deals 392
16.1.15 STEMCELL TECHNOLOGIES 394
16.1.15.1 Business overview 394
16.1.15.2 Products offered 394
16.1.15.3 Recent developments 400
16.1.15.3.1 Product launches 400
16.1.15.3.2 Deals 400
16.2 OTHER PLAYERS 401
16.2.1 ROOSTERBIO, INC. 401
16.2.2 MILTENYI BIOTEC 402
16.2.3 TRAKCEL 403
16.2.4 L7 INFORMATICS, INC. 404
16.2.5 REPLIGEN CORPORATION 405
16.2.6 MAK SYSTEM 406
16.2.7 ORIGEN BIOMEDICAL, INC. 407
16.2.8 IXCELLS BIOTECHNOLOGIES 408
16.2.9 K?RBER AG 410
16.2.10 KRISHGEN BIOSYSTEMS 411
17 RESEARCH METHODOLOGY 412
17.1 RESEARCH DATA 412
17.1.1 SECONDARY DATA 412
17.1.1.1 Key objectives of secondary research 413
17.1.2 PRIMARY DATA 413
17.1.2.1 Breakdown of primaries 414
17.1.2.2 Objectives of primary research 414
17.2 MARKET ESTIMATION METHODOLOGY 415
17.2.1 MARKET ESTIMATION 415
17.2.2 INSIGHTS FROM PRIMARY EXPERTS 417
17.2.3 TOP-DOWN APPROACH 418
17.3 MARKET GROWTH RATE PROJECTIONS 419
17.4 DATA TRIANGULATION 421
17.5 STUDY ASSUMPTIONS 421
17.6 RESEARCH LIMITATIONS 422
17.7 RISK ANALYSIS 423
?
18 APPENDIX 424
18.1 DISCUSSION GUIDE 424
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 428
18.3 CUSTOMIZATION OPTIONS 430
18.4 RELATED REPORTS 430
18.5 AUTHOR DETAILS 431

ページTOPに戻る

List of Tables/Graphs

TABLE 1 CELL THERAPY TECHNOLOGIES MARKET: INCLUSIONS & EXCLUSIONS 42
TABLE 2 IMPACT OF PORTER’S FIVE FORCES ON CELL THERAPY TECHNOLOGIES MARKET 61
TABLE 3 ROLE OF COMPANIES IN ECOSYSTEM IN CELL THERAPY TECHNOLOGIES MARKET 64
TABLE 4 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS, BY KEY PLAYER, 2022?2024 (USD) 66
TABLE 5 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS, BY REGION, 2022?2024 (USD) 67
TABLE 6 IMPORT VALUE FOR HS CODE 854330, 2020?2024 (USD THOUSAND) 70
TABLE 7 IMPORT VOLUME FOR HS CODE 854330, 2020?2024 (UNITS) 71
TABLE 8 EXPORT VALUE FOR HS CODE 854330, 2020?2024 (USD THOUSAND) 71
TABLE 9 EXPORT VOLUME FOR HS CODE 854330, 2020?2024 (UNITS) 72
TABLE 10 KEY CONFERENCES & EVENTS IN CELL THERAPY TECHNOLOGIES MARKET, JANUARY 2026?DECEMBER 2026 73
TABLE 11 US ADJUSTED RECIPROCAL TARIFF RATES 76
TABLE 12 KEY PRODUCT-RELATED TARIFF: HS CODES FOR PRODUCTS RELEVANT TO CELL THERAPY TECHNOLOGIES MARKET 78
TABLE 13 CELL THERAPY TECHNOLOGIES MARKET: INDICATIVE LIST OF PATENTS, 2025 84
TABLE 14 CASE STUDIES OF AI IMPLEMENTATION IN CELL THERAPY TECHNOLOGIES MARKET 88
TABLE 15 CLIENT’S READINESS TO ADOPT GENERATIVE MOLECULAR DESIGN IN CELL THERAPY TECHNOLOGIES MARKET 88
TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 18 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 19 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 20 VENDOR CERTIFICATIONS IN CELL THERAPY TECHNOLOGIES MARKET 95
TABLE 21 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR TOP FOUR END USERS 97
TABLE 22 KEY BUYING CRITERIA FOR CELL THERAPY TECHNOLOGIES PRODUCTS,
BY END USER 98
TABLE 23 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 102
TABLE 24 CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY REGION,
2023?2030 (USD MILLION) 103
TABLE 25 NORTH AMERICA: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET,
BY COUNTRY, 2023?2030 (USD MILLION) 103
TABLE 26 EUROPE: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 104
TABLE 27 ASIA PACIFIC: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET,
BY COUNTRY, 2023?2030 (USD MILLION) 104
TABLE 28 LATIN AMERICA: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET,
BY COUNTRY, 2023?2030 (USD MILLION) 105
TABLE 29 MIDDLE EAST: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2023?2030 (USD MILLION) 105
TABLE 30 GCC COUNTRIES: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET,
BY COUNTRY, 2023?2030 (USD MILLION) 105
TABLE 31 CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023?2030 (USD MILLION) 106
TABLE 32 CELL THERAPY EQUIPMENT MARKET, BY REGION, 2023?2030 (USD MILLION) 107
TABLE 33 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 107
TABLE 34 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 107
TABLE 35 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 108
TABLE 36 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 108
TABLE 37 MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY REGION,
2023?2030 (USD MILLION) 108
TABLE 38 GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 109
TABLE 39 CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2023?2030 (USD MILLION) 110
TABLE 40 NORTH AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 110
TABLE 41 EUROPE: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 110
TABLE 42 ASIA PACIFIC: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 111
TABLE 43 LATIN AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 111
TABLE 44 MIDDLE EAST: CELL PROCESSING EQUIPMENT MARKET, BY REGION,
2023?2030 (USD MILLION) 111
TABLE 45 GCC COUNTRIES: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 112
TABLE 46 SINGLE-USE EQUIPMENT MARKET, BY REGION, 2023?2030 (USD MILLION) 112
TABLE 47 NORTH AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 113
TABLE 48 EUROPE: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 113
TABLE 49 ASIA PACIFIC: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 113
TABLE 50 LATIN AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 114
TABLE 51 MIDDLE EAST: SINGLE-USE EQUIPMENT MARKET, BY REGION,
2023?2030 (USD MILLION) 114
TABLE 52 GCC COUNTRIES: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 114
TABLE 53 OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION,
2023?2030 (USD MILLION) 115
TABLE 54 NORTH AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 115
TABLE 55 EUROPE: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 116
TABLE 56 ASIA PACIFIC: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 116
TABLE 57 LATIN AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 116
TABLE 58 MIDDLE EAST: OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION,
2023?2030 (USD MILLION) 117
TABLE 59 GCC COUNTRIES: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 117
TABLE 60 MAJOR CELL THERAPY SYSTEMS & SOFTWARE, BY COMPANY 118
TABLE 61 CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY REGION,
2023?2030 (USD MILLION) 118
TABLE 62 NORTH AMERICA: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 119
TABLE 63 EUROPE: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 119
TABLE 64 ASIA PACIFIC: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 119
TABLE 65 LATIN AMERICA: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 120
TABLE 66 MIDDLE EAST: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY REGION, 2023?2030 (USD MILLION) 120
TABLE 67 GCC COUNTRIES: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 120
TABLE 68 CELL CULTURE VESSELS MARKET, BY REGION, 2023?2030 (USD MILLION) 121
TABLE 69 NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 121
TABLE 70 EUROPE: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 122
TABLE 71 ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 122
TABLE 72 LATIN AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 122
TABLE 73 MIDDLE EAST: CELL CULTURE VESSELS MARKET, BY REGION,
2023?2030 (USD MILLION) 123
TABLE 74 GCC COUNTRIES: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 123
TABLE 75 CELL ENGINEERING PRODUCTS OFFERED BY KEY COMPANIES 124
TABLE 76 CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2023?2030 (USD MILLION) 124
TABLE 77 NORTH AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 125
TABLE 78 EUROPE: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 125
TABLE 79 ASIA PACIFIC: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 125
TABLE 80 LATIN AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 126
TABLE 81 MIDDLE EAST: CELL ENGINEERING PRODUCTS MARKET, BY REGION,
2023?2030 (USD MILLION) 126
TABLE 82 GCC COUNTRIES: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 126
TABLE 83 OTHER CELL THERAPY PRODUCTS MARKET, BY REGION,
2023?2030 (USD MILLION) 127
TABLE 84 NORTH AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 127
TABLE 85 EUROPE: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 128
TABLE 86 ASIA PACIFIC: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 128
TABLE 87 LATIN AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 128
TABLE 88 MIDDLE EAST: OTHER CELL THERAPY PRODUCTS MARKET, BY REGION,
2023?2030 (USD MILLION) 129
TABLE 89 GCC COUNTRIES: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 129
TABLE 90 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023?2030 (USD MILLION) 131
TABLE 91 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE,
2023?2030 (USD MILLION) 132
TABLE 92 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2023?2030 (USD MILLION) 132
TABLE 93 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2023?2030 (USD MILLION) 132
TABLE 94 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY COUNTRY, 2023?2030 (USD MILLION) 133
TABLE 95 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY COUNTRY, 2023?2030 (USD MILLION) 133
TABLE 96 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2023?2030 (USD MILLION) 133
TABLE 97 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2023?2030 (USD MILLION) 134
TABLE 98 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2023?2030 (USD MILLION) 134
TABLE 99 CELL EXPANSION MARKET, BY REGION, 2023?2030 (USD MILLION) 135
TABLE 100 NORTH AMERICA: CELL EXPANSION MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 135
TABLE 101 EUROPE: CELL EXPANSION MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 135
TABLE 102 ASIA PACIFIC: CELL EXPANSION MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 136
TABLE 103 LATIN AMERICA: CELL EXPANSION MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 136
TABLE 104 MIDDLE EAST: CELL EXPANSION MARKET, BY REGION, 2023?2030 (USD MILLION) 136
TABLE 105 GCC COUNTRIES: CELL EXPANSION MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 137
TABLE 106 CELL ISOLATION MARKET, BY REGION, 2023?2030 (USD MILLION) 138
TABLE 107 NORTH AMERICA: CELL ISOLATION MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 138
TABLE 108 EUROPE: CELL ISOLATION MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 138
TABLE 109 ASIA PACIFIC: CELL ISOLATION MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 139
TABLE 110 LATIN AMERICA: CELL ISOLATION MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 139
TABLE 111 MIDDLE EAST: CELL ISOLATION MARKET, BY REGION, 2023?2030 (USD MILLION) 139
TABLE 112 GCC COUNTRIES: CELL ISOLATION MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 140
TABLE 113 CELL CHARACTERIZATION MARKET, BY REGION, 2023?2030 (USD MILLION) 140
TABLE 114 NORTH AMERICA: CELL CHARACTERIZATION MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 141
TABLE 115 EUROPE: CELL CHARACTERIZATION MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 141
TABLE 116 ASIA PACIFIC: CELL CHARACTERIZATION MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 141
TABLE 117 LATIN AMERICA: CELL CHARACTERIZATION MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 142
TABLE 118 MIDDLE EAST: CELL CHARACTERIZATION MARKET, BY REGION,
2023?2030 (USD MILLION) 142
TABLE 119 GCC COUNTRIES: CELL CHARACTERIZATION MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 142
TABLE 120 CELL COLLECTION MARKET, BY REGION, 2023?2030 (USD MILLION) 143
TABLE 121 NORTH AMERICA: CELL COLLECTION MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 144
TABLE 122 EUROPE: CELL COLLECTION MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 144
TABLE 123 ASIA PACIFIC: CELL COLLECTION MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 144
TABLE 124 LATIN AMERICA: CELL COLLECTION MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 145
TABLE 125 MIDDLE EAST: CELL COLLECTION MARKET, BY REGION,
2023?2030 (USD MILLION) 145
TABLE 126 GCC COUNTRIES: CELL COLLECTION MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 145
TABLE 127 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY REGION, 2023?2030 (USD MILLION) 146
TABLE 128 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2023?2030 (USD MILLION) 146
TABLE 129 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION,
BY COUNTRY, 2023?2030 (USD MILLION) 147
TABLE 130 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2023?2030 (USD MILLION) 147
TABLE 131 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2023?2030 (USD MILLION) 147
TABLE 132 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY REGION, 2023?2030 (USD MILLION) 148
TABLE 133 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2023?2030 (USD MILLION) 148
TABLE 134 PROCESS MONITORING & QUALITY CONTROL MARKET, BY REGION,
2023?2030 (USD MILLION) 149
TABLE 135 NORTH AMERICA: PROCESS MONITORING & QUALITY CONTROL MARKET,
BY COUNTRY, 2023?2030 (USD MILLION) 149
TABLE 136 EUROPE: PROCESS MONITORING & QUALITY CONTROL MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 150
TABLE 137 ASIA PACIFIC: PROCESS MONITORING & QUALITY CONTROL MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 150
TABLE 138 LATIN AMERICA: PROCESS MONITORING & QUALITY CONTROL MARKET,
BY COUNTRY, 2023?2030 (USD MILLION) 150
TABLE 139 MIDDLE EAST: PROCESS MONITORING & QUALITY CONTROL MARKET, BY REGION, 2023?2030 (USD MILLION) 151
TABLE 140 GCC COUNTRIES: PROCESS MONITORING & QUALITY CONTROL MARKET,
BY COUNTRY, 2023?2030 (USD MILLION) 151
TABLE 141 CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY REGION, 2023?2030 (USD MILLION) 152
TABLE 142 CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2023?2030 (USD MILLION) 152
TABLE 143 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING,
BY COUNTRY, 2023?2030 (USD MILLION) 152
TABLE 144 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING,
BY COUNTRY, 2023?2030 (USD MILLION) 153
TABLE 145 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2023?2030 (USD MILLION) 153
TABLE 146 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING,
BY REGION, 2023?2030 (USD MILLION) 153
TABLE 147 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2023?2030 (USD MILLION) 154
TABLE 148 CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY REGION, 2023?2030 (USD MILLION) 154
TABLE 149 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2023?2030 (USD MILLION) 155
TABLE 150 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION,
BY COUNTRY, 2023?2030 (USD MILLION) 155
TABLE 151 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2023?2030 (USD MILLION) 155
TABLE 152 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2023?2030 (USD MILLION) 156
TABLE 153 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY REGION, 2023?2030 (USD MILLION) 156
TABLE 154 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2023?2030 (USD MILLION) 156
TABLE 155 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023?2030 (USD MILLION) 158
TABLE 156 T-CELL THERAPY TECHNOLOGIES MARKET, BY REGION,
2023?2030 (USD MILLION) 159
TABLE 157 NORTH AMERICA: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 159
TABLE 158 EUROPE: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 159
TABLE 159 ASIA PACIFIC: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 160
TABLE 160 LATIN AMERICA: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 160
TABLE 161 MIDDLE EAST: T-CELL THERAPY TECHNOLOGIES MARKET, BY REGION,
2023?2030 (USD MILLION) 160
TABLE 162 GCC COUNTRIES: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 161
TABLE 163 STEM CELL THERAPY TECHNOLOGIES MARKET, BY REGION,
2023?2030 (USD MILLION) 162
TABLE 164 NORTH AMERICA: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 162
TABLE 165 EUROPE: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 162
TABLE 166 ASIA PACIFIC: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 163
TABLE 167 LATIN AMERICA: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 163
TABLE 168 MIDDLE EAST: STEM CELL THERAPY TECHNOLOGIES MARKET, BY REGION,
2023?2030 (USD MILLION) 163
TABLE 169 GCC COUNTRIES: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 164
TABLE 170 OTHER CELL THERAPY TECHNOLOGIES MARKET, BY REGION,
2023?2030 (USD MILLION) 164
TABLE 171 NORTH AMERICA: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 165
TABLE 172 EUROPE: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 165
TABLE 173 ASIA PACIFIC: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 165
TABLE 174 LATIN AMERICA: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 166
TABLE 175 MIDDLE EAST: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2023?2030 (USD MILLION) 166
TABLE 176 GCC COUNTRIES: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023?2030 (USD MILLION) 166
TABLE 177 CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 168
TABLE 178 CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY REGION,
2023?2030 (USD MILLION) 169
TABLE 179 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER,
BY COUNTRY, 2023?2030 (USD MILLION) 169
TABLE 180 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2023?2030 (USD MILLION) 170
TABLE 181 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2023?2030 (USD MILLION) 170
TABLE 182 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER,
BY COUNTRY, 2023?2030 (USD MILLION) 170
TABLE 183 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY REGION, 2023?2030 (USD MILLION) 171
TABLE 184 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER,
BY COUNTRY, 2023?2030 (USD MILLION) 171
TABLE 185 CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES,
BY REGION, 2023?2030 (USD MILLION) 172
TABLE 186 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 172
TABLE 187 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 173
TABLE 188 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 173
TABLE 189 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 173
TABLE 190 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023?2030 (USD MILLION) 174
TABLE 191 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2023?2030 (USD MILLION) 174
TABLE 192 CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS,
BY REGION, 2023?2030 (USD MILLION) 175
TABLE 193 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023?2030 (USD MILLION) 175
TABLE 194 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023?2030 (USD MILLION) 176
TABLE 195 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023?2030 (USD MILLION) 176
TABLE 196 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023?2030 (USD MILLION) 176
TABLE 197 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY REGION, 2023?2030 (USD MILLION) 177
TABLE 198 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023?2030 (USD MILLION) 177
TABLE 199 CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES,
BY REGION, 2023?2030 (USD MILLION) 178
TABLE 200 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 178
TABLE 201 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 179
TABLE 202 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 179
TABLE 203 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 179
TABLE 204 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2023?2030 (USD MILLION) 180
TABLE 205 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 180
TABLE 206 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2023?2030 (USD MILLION) 181
TABLE 207 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023?2030 (USD MILLION) 181
TABLE 208 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023?2030 (USD MILLION) 181
TABLE 209 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023?2030 (USD MILLION) 182
TABLE 210 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023?2030 (USD MILLION) 182
TABLE 211 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2023?2030 (USD MILLION) 182
TABLE 212 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023?2030 (USD MILLION) 183
TABLE 213 CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023?2030 (USD MILLION) 185
TABLE 214 CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023?2030 (USD MILLION) 186
TABLE 215 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023?2030 (USD MILLION) 187
TABLE 216 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023?2030 (USD MILLION) 187
TABLE 217 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023?2030 (USD MILLION) 187
TABLE 218 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023?2030 (USD MILLION) 188
TABLE 219 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023?2030 (USD MILLION) 188
TABLE 220 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023?2030 (USD MILLION) 188
TABLE 221 CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION,
2023?2030 (USD MILLION) 190
TABLE 222 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS,
BY COUNTRY, 2023?2030 (USD MILLION) 190
TABLE 223 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS,
BY COUNTRY, 2023?2030 (USD MILLION) 190
TABLE 224 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS,
BY COUNTRY, 2023?2030 (USD MILLION) 191
TABLE 225 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS,
BY COUNTRY, 2023?2030 (USD MILLION) 191
TABLE 226 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS,
BY REGION, 2023?2030 (USD MILLION) 191
TABLE 227 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS,
BY COUNTRY, 2023?2030 (USD MILLION) 192
TABLE 228 CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY REGION, 2023?2030 (USD MILLION) 193
TABLE 229 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023?2030 (USD MILLION) 193
TABLE 230 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES,
BY COUNTRY, 2023?2030 (USD MILLION) 193
TABLE 231 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023?2030 (USD MILLION) 194
TABLE 232 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023?2030 (USD MILLION) 194
TABLE 233 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY REGION, 2023?2030 (USD MILLION) 194
TABLE 234 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023?2030 (USD MILLION) 195
TABLE 235 CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY REGION,
2023?2030 (USD MILLION) 196
TABLE 236 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS,
BY COUNTRY, 2023?2030 (USD MILLION) 196
TABLE 237 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2023?2030 (USD MILLION) 196
TABLE 238 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS,
BY COUNTRY, 2023?2030 (USD MILLION) 197
TABLE 239 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS,
BY COUNTRY, 2023?2030 (USD MILLION) 197
TABLE 240 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS,
BY REGION, 2023?2030 (USD MILLION) 197
TABLE 241 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS,
BY COUNTRY, 2023?2030 (USD MILLION) 198
TABLE 242 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2023?2030 (USD MILLION) 200
TABLE 243 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 201
TABLE 244 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 202
TABLE 245 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023?2030 (USD MILLION) 202
TABLE 246 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023?2030 (USD MILLION) 202
TABLE 247 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023?2030 (USD MILLION) 203
TABLE 248 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023?2030 (USD MILLION) 203
TABLE 249 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023?2030 (USD MILLION) 203
TABLE 250 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023?2030 (USD MILLION)TABLE 251 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 205
TABLE 252 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023?2030 (USD MILLION) 205
TABLE 253 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023?2030 (USD MILLION) 205
TABLE 254 US: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023?2030 (USD MILLION) 206
TABLE 255 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023?2030 (USD MILLION) 206
TABLE 256 US: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 206
TABLE 257 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023?2030 (USD MILLION) 207
TABLE 258 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 208
TABLE 259 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023?2030 (USD MILLION) 208
TABLE 260 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023?2030 (USD MILLION) 208
TABLE 261 CANADA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING
BY TYPE, 2023?2030 (USD MILLION) 209
TABLE 262 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023?2030 (USD MILLION) 209
TABLE 263 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 209
TABLE 264 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023?2030 (USD MILLION) 210
TABLE 265 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 211
TABLE 266 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023?2030 (USD MILLION) 211
TABLE 267 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023?2030 (USD MILLION) 211
TABLE 268 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2023?2030 (USD MILLION) 212
TABLE 269 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023?2030 (USD MILLION) 212
TABLE 270 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 212
TABLE 271 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023?2030 (USD MILLION) 213
TABLE 272 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 214
TABLE 273 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023?2030 (USD MILLION) 214
TABLE 274 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023?2030 (USD MILLION) 215
TABLE 275 GERMANY: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2023?2030 (USD MILLION) 215
TABLE 276 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023?2030 (USD MILLION) 215
TABLE 277 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 216
TABLE 278 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023?2030 (USD MILLION) 216
TABLE 279 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 217
TABLE 280 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023?2030 (USD MILLION) 218
TABLE 281 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023?2030 (USD MILLION) 218
TABLE 282 UK: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023?2030 (USD MILLION) 218
TABLE 283 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023?2030 (USD MILLION) 219
TABLE 284 UK: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 219
TABLE 285 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023?2030 (USD MILLION) 219
TABLE 286 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 220
TABLE 287 FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023?2030 (USD MILLION) 221
TABLE 288 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023?2030 (USD MILLION) 221
TABLE 289 FRANCE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2023?2030 (USD MILLION) 221
TABLE 290 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023?2030 (USD MILLION) 222
TABLE 291 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 222
TABLE 292 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023?2030 (USD MILLION) 222
TABLE 293 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 223
TABLE 294 ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023?2030 (USD MILLION) 224
TABLE 295 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023?2030 (USD MILLION) 224
TABLE 296 ITALY: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023?2030 (USD MILLION) 224
TABLE 297 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023?2030 (USD MILLION) 225
TABLE 298 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 225
TABLE 299 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023?2030 (USD MILLION) 225
TABLE 300 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 226
TABLE 301 SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023?2030 (USD MILLION) 227
TABLE 302 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023?2030 (USD MILLION) 227
TABLE 303 SPAIN: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023?2030 (USD MILLION) 227
TABLE 304 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023?2030 (USD MILLION) 228
TABLE 305 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 228
TABLE 306 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023?2030 (USD MILLION) 228
TABLE 307 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 229
TABLE 308 REST OF EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023?2030 (USD MILLION) 230
TABLE 309 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023?2030 (USD MILLION) 230
TABLE 310 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023?2030 (USD MILLION) 230
TABLE 311 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023?2030 (USD MILLION) 231
TABLE 312 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023?2030 (USD MILLION) 231
TABLE 313 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023?2030 (USD MILLION) 231
TABLE 314 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 233
TABLE 315 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023?2030 (USD MILLION) 233
TABLE 316 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023?2030 (USD MILLION) 233
TABLE 317 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2023?2030 (USD MILLION) 234
TABLE 318 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023?2030 (USD MILLION) 234
TABLE 319 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023?2030 (USD MILLION) 234
TABLE 320 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023?2030 (USD MILLION) 235
TABLE 321 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 236
TABLE 322 CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023?2030 (USD MILLION) 236
TABLE 323 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023?2030 (USD MILLION) 236
TABLE 324 CHINA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023?